Better Health for All

ProQR's entire business model is dedicated to developing RNA therapies for severe rare and common genetic diseases, many of which currently lack approved treatments, indicating a revolutionary health impact.

The company focuses on correcting disease-causing mutations at the RNA level for conditions like Leber Congenital Amaurosis 10, Rett syndrome, cholestatic diseases, and cardiovascular diseases. As a research and development company that does not manufacture or distribute products for sale, ProQR generates no revenue from products with negative health outcomes. In 2024, ProQR's research and development costs were €36,356,000, while its net revenue was €18,905,000, meaning R&D investment was approximately 192% of net revenue. The company holds more than 20 published patent families for its RNA editing platform and successfully defended key patents in 2024. There is no evidence to score KPIs related to safety record, price accessibility, vulnerable reach, risk transparency, health externalities, health equity programs, healthcare workforce support, preventative health measures, healthcare data responsibility, global health crisis response, mental health initiatives, nutrition and food safety, healthcare education, addiction mitigation, or clinical trial ethics.

Kind to Animals

ProQR states that the welfare of animals in preclinical studies is of great importance, and it actively pursues the 3R principles (Reduce, Refine, and Replace).

The company commits to using alternatives to animal research whenever possible, performing animal experiments only if no alternatives such as in silico, in-vitro, or ex-vivo studies exist. However, preclinical studies still utilize in vivo animal models, including mice and non-human primates, with up to 40% editing observed in mice and up to 50% in non-human primates. The company does not provide specific annual animal usage numbers or transparent reduction targets. Approval by institutional or national animal care and use committees is required prior to the execution of in vivo studies. External Contract Research Organization (CRO) facilities are audited by ProQR prior to contracting to ensure compliance with international standards for animal housing, husbandry, and welfare.

No War, No Weapons

The provided article explicitly states that it does not contain any data relevant to the 'No War, No Weapons' value or any metrics related to arms contracts, peacebuilding, or conflict divestment.

Therefore, no KPIs can be scored based on the available evidence.

Safe & Smart Tech

ProQR Therapeutics N.V. states it has been in material compliance with all applicable data privacy and security laws and regulations, including HIPAA, HITECH Act, and the European Union General Data Protection Regulation (GDPR).

The company aims to process data in accordance with GDPR and has implemented GDPR-recognized safeguards for international data transfers, such as the EU-US Data Privacy Framework and standard contractual clauses. ProQR collects only necessary information and limits data retention, with personal data used for inquiries withheld for a maximum of two years. Job application data is stored for a maximum of four weeks post-application procedure, or up to a year with permission. Health data is retained only as long as necessary for interview arrangements. Users are provided with various data subject rights under GDPR, including the right to access, rectification, restriction of processing, erasure (right to be forgotten), data portability, and objection. The company does not use fully automated decision-making technologies. There are no documented incidents of unauthorized data use or data breaches.